The fever caused by respiratory infections
Conditions
Interventions
Experimental group:Right-handed ibuprofen oral suspension
Control group:Ibuprofen oral suspension (Melin)
Sponsors
Affiliated hangzhou first people's hospital, zhejiang university school of medicine
Eligibility
Sex/Gender
All
Age
1 Years to 12 Years
Inclusion criteria
Inclusion criteria: 1. The guardian consents to participate in the study, signs an informed consent form, and is able to cooperate with follow-up visits. 2. Children aged 1 to 12 years, with no gender restrictions. 3. Acute respiratory infections with fever. 4. Symptoms of fever, with an axillary temperature of 38.5°C or less but above 38.5°C. 5. The onset of clinical symptoms for this current episode is within the last 72 hours.
Exclusion criteria
Exclusion criteria: 1. Antipyretic drugs (including compound preparations containing antipyretic ingredients and Traditional Chinese Medicine Patent Prescriptions) used in the past 6 hours; 2. The use of glucocorticoids in the past 24 hours; 3. Severe abnormal liver and kidney function (ALT or AST > 2 times normal value); Creatinine (Cr) > 1.5 times normal line; 4. Persons who have signs of dehydration or a high fever threat at the time of their visit and who have had a high-temperature threat within the past 6 months; 5. Severe malnutrition; 6. Accompanied heart failure or other organ failure; 7. Children with a diagnosed tumor; 8. ulcers in the digestive tract or active bleeding; 9. Children with symptoms such as tuberculosis, sepsis, rheumatic fever, typhoid, localized pustular lesions and prolonged fever; 10. Allergic to this type of medication; asthma, rhinitis, or urticaria triggered by the use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs); 11.Chronic disorders of liver, kidney, endocrinology (such as uncontrolled diabetes mellitus), blood, heart, respiratory system, genetic and metabolic disorders and other critical illnesses; 12. Central nervous system disorders; 13. Rheumatic immune diseases (such as SLE, mixed connective tissue disease, etc.) 14. Have participated in clinical trials of other drugs within one month prior to the screening; 15. Other circumstances are considered unfit for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Temperature change 4 hours after administration; | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of people with normal body temperature (<= 37.2?);Life signs, gastrointestinal symptoms, allergic reactions, other adverse events;Other adverse events;Temperature change 6 hours after administration;Change in fever comfort score;The average time for normalizing body temperature (= 37.2?); | — |
Countries
China
Contacts
Public ContactChunming Jiang
Affiliated hangzhou first people's hospital, zhejiang university school of medicine
Outcome results
None listed